Skip to main content
SpringerLink
Log in

Buccal and intranasal lorazepam clinical pharmacokinetics: can it adequately compete with intravenous lorazepam in pediatric care patients?

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Anderson M (2010) Benzodiazepines for prolonged seizures. Arch Dis Child Ed Prac 95:183–189

    Article  Google Scholar 

  2. Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J (2008) Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics 121:e58–e64

    Article  PubMed  Google Scholar 

  3. Anderson M, Tambe P, Sammons H, Mulla H, Cole R, Choonara I (2012) Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers. Eur J Clin Pharmacol. 68:155–159

    Google Scholar 

  4. Appleton R, Choonara I, Martland T, Phillips B, Scott R, Whitehouse W (2000) The treatment of convulsive status epilepticus in children. Arch Dis Child 83:415–419

    Article  PubMed  CAS  Google Scholar 

  5. Camu F, Maes V, Van de Velde A, Sevens C (1988) Lorazepam fast-dissolving drug formulation (FDDF) and intravenous administrations as anaesthetic premedicants: a pharmacokinetic analysis. Eur J Anaesthesiol 5:261–268

    PubMed  CAS  Google Scholar 

  6. Nielsen-Kudsk F, Jensen TS, Magnussen I, Jakobsen P, Jensen PB, Mondrup K, Petersen T (1983) Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. Acta Pharmacol Toxicol (Copenh) 52:121–127

    Article  CAS  Google Scholar 

  7. Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC (2001) Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 41:1225–1231

    Article  PubMed  CAS  Google Scholar 

  8. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1982) Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 71:248–252

    Article  PubMed  CAS  Google Scholar 

  9. Lau SWJ, Slattery JT (1989) Absorption of diazepam and lorazepam following intranasal administration. Int J Pharm 54:171–174

    Article  Google Scholar 

  10. Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan P, Lichenstein R, Stanley RM, Davis CO, Gordon S, Baren JM, van den Anker JN (2011) Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients with and without Status Epilepticus. J Pediatr. [Epub ahead of print]

  11. Arya R, Gulati S, Kabra M, Sahu JK, Kalra V (2011) Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia 52:788–793

    Article  PubMed  CAS  Google Scholar 

  12. U.S. National Institutes of Health (2008) Randomized trial comparing 3 routes of delivering lorazepam to children. Available at: http://clinicaltrials.gov/ct2/show/NCT00343096. Accessed 29 Nov 2011

  13. Davies A, Finn A, Tagarro I (2011) Intra- and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis. Clin Drug Investig 31:317–324

    PubMed  CAS  Google Scholar 

  14. Darwish M, Hamed E, Messina J (2010) Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. Perspect Medicin Chem 4:11–21

    Article  PubMed  CAS  Google Scholar 

  15. Finn A, Collins J, Voyksner R, Lindley C (2005) Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. J Clin Pharmacol 45:1383–1390

    Article  PubMed  CAS  Google Scholar 

  16. Anttila M, Penttilä J, Helminen A, Vuorilehto L, Scheinin H (2003) Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 56:691–693

    Article  PubMed  Google Scholar 

Download references

Competing interests

None.

Author information

Authors and Affiliations

  1. Vanthys Pharmaceutical Development [P] Ltd, Phoenix Pinnacle, #46, 3rd floor, Ulsoor Road, Bangalore, 560042, India

    Nuggehally R. Srinivas

Authors
  1. Nuggehally R. Srinivas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nuggehally R. Srinivas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Srinivas, N.R. Buccal and intranasal lorazepam clinical pharmacokinetics: can it adequately compete with intravenous lorazepam in pediatric care patients?. Eur J Clin Pharmacol 68, 1221–1223 (2012). https://doi.org/10.1007/s00228-012-1242-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1242-5

Keywords

Search

Navigation